Skip to main content
ACR Convergence 2023 Main banner
Final Program


Schedule at a Glance
Legend
Session Format
In Person
In Person
Livestreamed
Livestreamed
On Demand
On Demand
Back

M. Elaine Husni, MD, MPH

Cleveland Clinic
Cleveland, OH, United States

Dr. M. Elaine Husni is Vice Chair, and Director, Arthritis and Musculoskeletal Center in the Orthopedic and Rheumatologic Institute at the Cleveland Clinic. She is currently Director of Clinical Outcomes research. Dr. Husni is an assistant professor at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. She trained in Rheumatology at the Brigham and Women's Hospital at Harvard Medical School and received her MD and MPH degrees from Boston University School of Medicine.

Dr. Husni's most recent research focus is examining cardiovascular (CV) outcomes of patients with psoriasis, and psoriatic arthritis. Her work focuses on potential mechanism of accelerated CV disease in these patients by examining proatherogenic or inflammatory lipids and biomarkers as well as novel therapeutics for psoriatic diseases.

She is also involved in a number of rheumatology clinical trials at the Cleveland Clinic focusing on osteoarthritis, psoriatic arthritis, and rheumatoid arthritis including the PRECISION trial. This trial focuses on the cardiovascular risks associated among 3 common NSAIDs – ibuprofen, naproxen, and celecoxib. She is a past recipient of the Physician Scientist Development Award and Clinical Investigator Award by the American College of Rheumatology for her research and funded by the National Psoriasis Foundation. Her research is also funded by an NIH RO1 grant.

Presentation(s):

  • 0505: Factors Associated with Minimal Disease Activity in Psoriatic Arthritis: Insights from a Registry-Based Study

    Sunday, November 12, 2023
    9:00 AM – 11:00 AM PT

    Disclosure(s): AbbVie: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Amgen: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Bristol-Myers Squibb: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Eli Lilly: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Janssen: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Pfizer: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); UCB: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing)

  • 0527: Bimekizumab Treatment Impact on Pain and Fatigue in Patients with Active Psoriatic Arthritis Who Were Biologic DMARD‑Naïve or Had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3 Studies

    Sunday, November 12, 2023
    9:00 AM – 11:00 AM PT

    Disclosure(s): AbbVie: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Amgen: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Bristol-Myers Squibb: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Eli Lilly: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Janssen: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Pfizer: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); UCB: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing)

  • 2242: Irrespective of the Number of Erosions at Baseline, Patients with Psoriatic Arthritis Treated with Ixekizumab Show Improved Clinical Outcomes

    Tuesday, November 14, 2023
    9:00 AM – 11:00 AM PT

    Disclosure(s): AbbVie: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Amgen: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Bristol-Myers Squibb: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Eli Lilly: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Janssen: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Pfizer: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); UCB: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing)

  • 15W112: Getting Skin and Joint in the Game: Key Players in the Psoriatic Arthritis Microenvironment

    Wednesday, November 15, 2023
    9:15 AM – 10:15 AM PT

    Disclosure(s): AbbVie: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Amgen: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Bristol-Myers Squibb: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Eli Lilly: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Janssen: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Pfizer: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); UCB: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing)